Human health and medicine

Seema Verma

Seema Verma is an American health policy executive who led the Centers for Medicare & Medicaid Services from 2017 to 2021 under President Trump, later joining Oracle Health.

Segmental arterial mediolysis is a rare, non-inflammatory arterial disease that weakens medium-sized artery walls, causing dissections, aneurysms, and hemorrhage, most often in abdominal visceral arteries.

Segmental myoclonus

Segmental myoclonus (ICD-11 8A06.1) is rhythmic myoclonus limited to one or contiguous spinal or brainstem segments, typically 1–3 Hz with 50–500 ms EMG bursts, no EEG correlate, caused by local lesions, and often refractory to clonazepam and botulinum toxin.

Segmental odontomaxillary dysplasia

Segmental odontomaxillary dysplasia, first described in 1987, is a rare developmental condition in which one side of the upper jaw grows excessively, with missing teeth.

Segmental spinal dysgenesis

Segmental spinal dysgenesis (SSD), also called spinal segmental dysgenesis, is a rare congenital spinal dysraphism with localized agenesis of the lumbar or thoracolumbar spine, severe kyphoscoliosis, segmental spinal cord malformation, paraparesis, and lower limb deformities; first defined by Scott et al in 1988.

Segmental venous malformation

Segmental venous malformation, also called Bockenheimer syndrome or genuine diffuse phlebectasia, is an ultra-rare congenital, progressive venous malformation of the limbs affecting veins of all sizes, with pain, swelling, and ulceration.

Segmentectomy

Segmentectomy, first described in 1939, is an anatomical lung resection removing one or more bronchopulmonary segments to treat small tumors while preserving healthy tissue, an alternative to lobectomy.

Segregation analysis

Segregation analysis is a statistical genetics method that tests whether a trait's transmission through families fits Mendelian inheritance at a single locus, estimating parameters such as transmission probabilities and penetrance.

SEIR model

The SEIR model, or SEIR epidemic model, is an epidemiological model dividing a population into susceptible, exposed, infectious, and recovered classes to simulate disease spread.

Seismocardiography

Seismocardiography (SCG) is a noninvasive method that records the low-frequency vibrations the beating heart produces at the chest surface, first recorded by P. Mounsey in 1957.

Seizure

Seizure: transient episode of abnormal synchronous electrical brain activity lasting seconds to minutes. Classified by ILAE 2017 as focal, generalized, or unknown onset; epilepsy requires two or more unprovoked seizures.

Seladelpar

Seladelpar (Livdelzi) is a PPAR-delta agonist, 10 mg daily oral capsule for primary biliary cholangitis with inadequate UDCA response or intolerance; FDA accelerated approval August 2024, MHRA approval January 2025, NICE recommended 2026.

Selatogrel

Selatogrel (ACT-246475) is an investigational reversible P2Y12 inhibitor given subcutaneously, in Phase 3 (SOS-AMI, NCT04957719) for self-administration at suspected heart attack; developed by Idorsia, now Viatris.

Seldinger technique

The Seldinger technique is a percutaneous access method introduced by Sven Ivar Seldinger in 1953, in which a guidewire passed through a hollow needle allows catheter placement without surgical cut-down.

SELECT - PsA 1 trial

SELECT-PsA 1 (NCT03104400), AbbVie-funded phase 3 trial of upadacitinib (Rinvoq) 15 and 30 mg versus placebo and adalimumab in 1,704 psoriatic arthritis patients with inadequate non-biologic DMARD response; ACR20 70.6/78.5% versus 36.2% placebo at week 12.

SELECT trial (NCT03574597)

SELECT (NCT03574597), the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity trial, was Novo Nordisk's phase 3 trial showing once-weekly semaglutide 2.4 mg cut major adverse cardiovascular events 20% in 17,604 adults with cardiovascular disease and overweight or obesity but no diabetes.

SELECT-AXIS 2 trial

SELECT-AXIS 2 (NCT04169373) is AbbVie's phase 3 program of upadacitinib 15 mg in axial spondyloarthritis; its nr-axSpA study showed ASAS40 45% vs 23% at week 14.

SELECT-BEYOND trial

SELECT-BEYOND (NCT02706847): AbbVie-funded phase 3 trial of upadacitinib 15/30 mg in rheumatoid arthritis refractory to biologic DMARDs; ACR20 65%/56% vs 28% placebo at week 12, 5-year extension data.

SELECT-EARLY trial

SELECT-EARLY (NCT02706873), a phase 3 SELECT-program trial of upadacitinib (Rinvoq), tested 15/30 mg once-daily monotherapy against methotrexate in 945 MTX-naive rheumatoid arthritis patients, showing superior efficacy through 5 years.

SELECT-NEXT trial

SELECT-NEXT (NCT02675426) was a phase 3 trial of upadacitinib 15 mg and 30 mg plus csDMARDs in rheumatoid arthritis with inadequate csDMARD response; 661 patients, ACR20 64-66% versus 36% placebo, 5-year extension data reported.

SELECT2 trial

SELECT2 (NCT03876457) was a 352-patient international randomized trial showing endovascular thrombectomy plus medical care improved functional outcomes over medical care alone in large-core ischemic stroke within 24 hours.

Selective androgen receptor modulator

A selective androgen receptor modulator, or SARM, is a drug candidate that activates the androgen receptor in bone and muscle while sparing the prostate; none is FDA-approved.

Selective IgM deficiency

Selective IgM deficiency (SIgMD) is a rare primary immunodeficiency, first described in 1967, in which serum IgM is absent or low while other antibody levels are normal.

Selective internal radiation therapy

Selective internal radiation therapy (SIRT), also called radioembolization, is a liver-directed cancer treatment that injects radioactive microspheres into arteries feeding liver tumors, sparing normal liver.

Oct 20, 2026

Selective intrauterine growth restriction

Selective intrauterine growth restriction (sIUGR, or sFGR) is one fetus growing restrictively in a twin pregnancy, affecting 10–25% of monochorionic twins; classified Gratacós Types I–III by umbilical artery Doppler, with type-dependent mortality and management.

Selective mutism

Selective mutism is a childhood anxiety disorder (DSM-5-TR, ICD-11; formerly elective mutism) in which a child speaks in some settings but consistently cannot speak where expected, such as school; onset ages 3–6, prevalence 0.2–1.6%, treated with CBT and SSRIs.